Acrobiosystems Co

Acrobiosystems Co Net Debt

The Net Debt of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 55.28 M CNY. In the previous year, Net Debt was -34.28 M CNY — a change of -261.26% (higher).

Net Debt

55.28 MCNY

YoY

-261.26%

Last updated:

Net Debt of Acrobiosystems Co is 2025 55.28 M CNY. Net Debt of Acrobiosystems Co was 2024 -34.28 M CNY. It decreases by -261.26% higher compared to the previous year.

The Acrobiosystems Co Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-34.28 M CNY
Jan 1, 2025
55.28 M CNY
The Acrobiosystems Co Net Debt history
YEARNet DebtYoY
55.28 MCNY-261.26%
-34.28 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Net Debt of Acrobiosystems Co is 55.28 M CNY in 2025.

Net Debt of Acrobiosystems Co changed from -34.28 M CNY to 55.28 M CNY, representing a -261.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co